tiprankstipranks
Trending News
More News >

Arvinas price target lowered to $9.50 from $10 at Citi

Citi lowered the firm’s price target on Arvinas (ARVN) to $9.50 from $10 and keeps a Neutral rating on the shares. The firm says Pfizer’s decision to no longer pursue vepdeg Phase 3 combos has given Arvinas’ pipeline new important.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue